The market growth in North America can be attributed to the rising geriatric population, frequent US FDA approvals for innovative electroceutical devices, and growing adoption of minimally invasive/non-invasive surgeries for treatment of several diseases owing to growing awareness among patients related to electroceuticals. The geriatric population is more inclined to the risk of heart strokes. According to WHO, the incidence and prevalence rate of heart attacks are highest in North America, which is responsible for 0.7 million fatalities each year.
Furthermore, according to the Heart & Stroke Foundation in Canada, 1.6 million fatalities occur every year due to stroke and at least 1.3 million Canadians live with heart disease. Moreover, the rate of adoption of advanced techniques is the highest in North America. This fact is further supporting the growth of electroceuticals market in North America. Apart from heart diseases, high prevalence of hearing loss, growing prevalence of neurological disorders, and expected approvals for retinal implants in the US is again contributing to the growth of electroceuticals market in North America. Also, the improvements in technology such as miniaturization, better battery technology, wearable, wireless micro-current stimulation are anticipated to increase the market demand in North America.
Abbott Laboratories Inc., Advanced Bionics AG, Axonics Modulation Technologies Inc., Boston Scientific Corp., BioElectronics Corp., Cochlear Ltd. are the manufacturer, and supplier of medical devices such as pacemaker, defibrillator,vagus nerve stimulator sand has its facilities in more than 40 countries and includes over 100 brands in its product portfolio. These players adopt various strategies in order to remain competitive in the global market. Some of the strategies followed by market players include mergers and acquisitions, product offering expansion, geographical expansion, and partnerships and collaborations.
In August 2019, Stanford initiated the responsive neuromodulation to control overeating. It will study the feasibility of using NeuroPace's RNS responsive neuromodulation system to stimulate the nucleus accumbens to control overeating in people with treatment-refractory obesity. In June 2018, the company launched the Next-Gen RNS System for the treatment of refractory epilepsy. It is a type of brain-computer interface which can continuously monitor brain waves and can automatically respond with imperceptible electrical pulses before seizures occur.
The market study of the North American Electroceuticals market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for medical device manufacturing companies, distributors and suppliers, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
1. North American Electroceuticals market Research and Analysis by Product
2. North American Electroceuticals market Research and Analysis by End-users
The Report Covers
- Comprehensive research methodology of the North American electroceuticals market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the North American Electroceuticals market.
- Insights about market determinants which are stimulating the North American Electroceuticals market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.3. Rules & Regulations
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
5.1.1. Cardioverter Defibrillators and Cardiac Pacemaker
5.1.2. Deep Brain Stimulators
188.8.131.52. Parkinson’s Disease
5.1.3. Spinal Cord Stimulators
184.108.40.206. Failed Back Syndrome
5.1.4. Vagus Nerve Stimulators
5.1.5. Cochlear Implants
220.127.116.11. Sensorineural Hearing Loss
5.1.6. Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)
18.104.22.168. Urinary Incontinence
22.214.171.124. Treatment-Resistant Depression
5.2. North American Electroceuticals Market by End-Users
5.2.1. Hospitals and Clinics
5.2.2. Research Institutes
7.2. Advanced Bionics AG
7.3. Axonics Modulation Technologies Inc.
7.4. Boston Scientific Corp.
7.5. BioElectronics Corp.
7.6. Cochlear Ltd.
7.7. Demant A/S
7.8. Edwards Lifesciences Corp.
7.9. Getinge AB
7.10. GlaxoSmithKline PLC
7.11. Medtronic PLC
7.12. Sonova Holding AG
7.13. Zoll Medical Corp.
A selection of companies mentioned in this report includes:
- Abbott Laboratories Inc.
- Advanced Bionics AG
- Axonics Modulation Technologies Inc.
- Boston Scientific Corp.
- BioElectronics Corp.
- Cochlear Ltd.
- Demant A/S
- Edwards Lifesciences Corp.
- Getinge AB
- GlaxoSmithKline PLC
- Medtronic PLC
- Sonova Holding AG
- Zoll Medical Corp.